Sugi Predict

Sugi Predict / Compounds / SCHEMBL5351775

SCHEMBL5351775

SCHEMBL5351775

c1ccc(-c2ccc(C3(c4ccc(-c5ccccc5)cc4)c4ccccc4-c4ccccc43)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.63
▸ KMT2A Q03164 3/20 0.63
▸ LMNA P02545 3/20 0.63
▸ MAPT P10636 2/20 0.63
▸ SMN1; SMN2 Q16637 2/20 0.63
▸ KDM4E B2RXH2 1/20 0.63
▸ OPRK1 P41145 1/20 0.63
▸ ESR1 P03372 1/20 0.47
▸ ESR2 Q92731 1/20 0.47
▸ POLB P06746 1/20 0.46
▸ PDK2 Q15119 4/20 0.44
▸ TDP1 Q9NUW8 2/20 0.43
▸ THRB P10828 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.41
▸ MAPK1 P28482 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ TAAR1 Q96RJ0 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ MMP3 P08254 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18978407 0.98 MEN1 (0.61) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL18184916 0.90 MMP3 (0.56) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL29547870 0.89 MEN1 (0.52) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL15866650 0.89 MEN1 (0.52) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL18287538 0.89 MEN1 (0.52) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL29370613 0.89 MEN1 (0.52) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL346270 0.89 MEN1 (0.52) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL30516188 0.88 MEN1 (0.71) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL14122566 0.88 MEN1 (0.71) MEN1KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL23079515 0.87 MEN1 (0.50) MEN1KMT2ALMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189877-B2 Arylamine derivatives having fluorene skeleton, synthetic intermediates thereof, processes of producing those, and organic electrolumivescene devices TOSCH CORPORATION (JP) 2007-03-13 — — US disclosed
EP-1400578-B1 Electrolumisescent 9,9-bis(4-amino)-1,1'-biphenyl)fluorene derivatives TOSOH CORP (JP) 2005-11-30 — — EP disclosed
US-20040110958-A1 Novel arylamine derivatives having fluorene skeleton, synthetic intermediates thereof, processes of producing those, and organic electrolumivescene devices TOSOH CORPORATION 2004-06-10 — — US disclosed
EP-1400578-A1 Electrolumisescent 9,9-bis(4-amino)-1,1'-biphenyl)fluorene derivatives Tosoh Corporation (JP) 2004-03-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110958-A1 Novel arylamine derivatives having fluorene skeleton, synthetic intermediates thereof, processes of producing those, and organic electrolumivescene devices AHR, NAT1, AR MEN1 3318/4885KMT2A 1459/4885LMNA 2722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.